Type II Diabetes Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
The primary objective of this study is to compare the rate of healing as well as percent of
wounds healed in Type II diabetic patients with chronic foot ulcerations receiving
sitagliptin versus placebo.
The hypothesis for this study is that subjects receiving daily doses of sitagliptin in
combination with their regular antihyperglycemic medications will result in increased
healing rates as well as a greater number of healed wounds as compared to subjects receiving
placebo and their regular antihyperglycemic medications.
Status | Terminated |
Enrollment | 1 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male or female age >18 - Type II Diabetes with glycated hemoglobin (hemoglobin A1C) of < 11 - Currently on an oral hyperglycemic medication other than sitagliptin - A chronic wound defined as the lack of wound healing progress of <15% per week or 50% over a month period - Ankle brachial index of > 0.80 - Wound located on the foot or ankle (Wagner Grade 1,2) - Able to comply with the requirements of the research trial Exclusion Criteria: - Current use of dipeptidyl-peptidase four (DPP-4) inhibitor or glucagon like peptide one (GLP-1)agonist - End stage renal disease - Currently enrolled in another research trial that involves treatment of the wound - Active infection of the wound - Wound that probes to bone with osteomyelitis (Wagner Grade 3) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Medstar Georgetown University Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Georgetown University | Merck Sharp & Dohme Corp. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Wounds Healed | Compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo. | 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04569214 -
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
|
Phase 2 | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01698528 -
Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration
|
N/A | |
Completed |
NCT00985114 -
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
|
N/A | |
Active, not recruiting |
NCT05120219 -
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04893135 -
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
|
N/A | |
Not yet recruiting |
NCT05108350 -
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02586129 -
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
|
Phase 3 | |
Completed |
NCT02914743 -
Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes
|
N/A | |
Completed |
NCT04540016 -
Mass Balance and Biotransformation of [14C]HSK7653 in Human
|
Phase 1 | |
Completed |
NCT02429258 -
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
|
Phase 4 | |
Completed |
NCT01055223 -
Fracture Risk With Thiazolidinediones
|
N/A | |
Terminated |
NCT02365233 -
Fatty Liver Study in Patients With Type II Diabetes
|
Phase 4 | |
Completed |
NCT05878587 -
Burger Allen Exercises in Knee OA With Type II Diabetes
|
N/A | |
Completed |
NCT04768673 -
A Study to Investigate the PK and Safety of CKD-393
|
Phase 1 | |
Not yet recruiting |
NCT05028140 -
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
|
Phase 3 | |
Terminated |
NCT01804777 -
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
|
Early Phase 1 | |
Completed |
NCT01619332 -
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06387433 -
Effectiveness of an mHealth Mobile App
|
N/A | |
Completed |
NCT01881074 -
Periodontal Treatment Response in Type II Diabetic Patients
|